{"id":"NCT00764790","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children","officialTitle":"Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10-01","primaryCompletion":"2009-03-05","completion":"2009-06-01","firstPosted":"2008-10-02","resultsPosted":"2010-07-27","lastUpdate":"2018-07-31"},"enrollment":3317,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Fluarix","otherNames":[]},{"type":"BIOLOGICAL","name":"Fluzone","otherNames":[]}],"arms":[{"label":"Fluarix Dose A Group","type":"EXPERIMENTAL"},{"label":"Fluarix Dose B Group","type":"EXPERIMENTAL"},{"label":"Fluzone Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline Biologicals' seasonal influenza vaccine, Fluarix, compared to Fluzone (a US-licensed vaccine) in children, 6 to 35 months of age.","primaryOutcome":{"measure":"Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains","timeFrame":"Day 0 (PRE), Day 28 or Day 56 (POST)","effectByArm":[{"arm":"Fluarix Dose A Group","deltaMin":10.4,"sd":null},{"arm":"Fluarix Dose B Group","deltaMin":10.6,"sd":null},{"arm":"Fluzone Group","deltaMin":10.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":69,"countries":["United States","Hong Kong","Mexico","Taiwan","Thailand"]},"refs":{"pmids":["29465480","23782962"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":1107},"commonTop":["Pain","Irritability","Drowsiness","Loss of appetite","Redness"]}}